A pivotal new study published in the November issue of Plastic and Reconstructive Surgery—the official medical journal of the American Society of Plastic Surgeons (ASPS)—has identified a concerning correlation that could reshape how surgeons evaluate candidates for body contouring procedures. Researchers have found that patients with a documented history of COVID-19 infection face a significantly higher risk of developing venous thromboembolism (VTE) following a panniculectomy.
As the medical community continues to navigate the long-term physiological aftermath of the global pandemic, this finding suggests that the hypercoagulable state often induced by COVID-19 may persist long after the initial infection has cleared, necessitating a re-evaluation of pre-operative risk assessment protocols.
The Core Findings: A Shift in Risk Assessment
The study, which analyzed over 7,000 surgical cases, highlights a clear divide in post-operative outcomes. While VTE—a collective term for life-threatening conditions including deep vein thrombosis (DVT) and pulmonary embolism (PE)—has always been a critical concern for plastic surgeons, the emergence of COVID-19 has introduced a new, complex variable into the clinical equation.
Lead author Mary Newland, BS, a medical student at Penn State College of Medicine, notes that while standard preventative measures, such as the use of anticoagulant medications, remain the bedrock of care, the "COVID-factor" appears to be an independent, predisposing risk factor that traditional scoring systems may not fully account for.
"Our findings suggest that past COVID may be an additional predisposing risk factor for VTE among patients undergoing panniculectomy," says Newland. "This may have implications for assessment and prevention of surgical risks of body contouring surgery after major weight loss."
Understanding the Procedure: Why Panniculectomy?
To understand the gravity of these findings, one must distinguish between cosmetic body contouring and functional reconstruction. A panniculectomy is a surgical procedure designed to remove the "pannus"—a hanging apron of excess skin and fat that often develops in the lower abdomen following massive weight loss.
Unlike aesthetic surgeries, a panniculectomy is frequently classified as a medically necessary or "functional" procedure. Patients seeking this surgery often suffer from chronic dermatological issues, such as severe rashes, fungal infections, ulcerations, and physical mobility limitations caused by the weight and discomfort of the overhanging tissue. Because these patients are often managing the sequelae of significant weight fluctuations, they already represent a demographic that requires careful VTE risk stratification. The discovery that prior COVID-19 infection effectively doubles the risk of blood clots represents a significant challenge for surgeons aiming to improve the quality of life for this vulnerable patient population.
Chronology of the Research
The study was designed to bridge the gap between anecdotal clinical observations and statistical certainty. To achieve this, the researchers performed a comprehensive analysis of national hospital data spanning a seven-year period, from 2017 to 2023.
The Pre-Pandemic Baseline (2017–March 2020)
Before the onset of the pandemic, the rates of VTE following panniculectomy were relatively stable. During this period, surgeons relied heavily on the Caprini Risk Assessment Model, a widely accepted tool used to categorize patients by their predisposition to blood clots based on age, BMI, surgical duration, and underlying medical conditions.
The Pandemic Transition (March 2020–2023)
As the pandemic progressed, clinical data began to emerge suggesting that COVID-19 was not merely a respiratory disease but a systemic vascular challenge. The study tracked 7,114 patients, split into two distinct cohorts:
- The Pre-Pandemic Cohort: 3,015 patients who underwent surgery before March 2020.
- The Post-Pandemic Cohort: 4,099 patients who underwent surgery after the virus had become endemic.
Initially, the aggregate data suggested that the VTE rates remained relatively consistent between the two groups (3.2% pre-pandemic vs. 3.0% post-pandemic). However, this aggregate data masked a more nuanced and dangerous trend hidden within the post-pandemic group.
Supporting Data: The COVID-19 Disparity
The most striking evidence emerged when researchers drilled down into the post-pandemic cohort to compare patients with a documented history of COVID-19 against those who had not contracted the virus.
The findings were stark:
- Non-COVID patients: Experienced a 2.5% rate of VTE.
- Patients with a history of COVID-19: Experienced a 4.9% rate of VTE.
This represents a statistically significant increase in risk. Importantly, the researchers controlled for other common VTE triggers—such as existing heart, lung, and blood vessel diseases—ensuring that the elevated risk could be attributed to the history of COVID-19 rather than other confounding variables.
The mechanism, as suggested by the authors, is likely linked to the systemic "hypercoagulability" (a tendency for the blood to clot more easily) that characterizes the post-COVID state. Even after recovery, the endothelial damage and inflammatory cascades triggered by the virus may leave the cardiovascular system in a state of heightened sensitivity to the trauma of major surgery.
Clinical Implications: The Need for New Protocols
The implications of these findings are profound for plastic and reconstructive surgeons worldwide. If a history of COVID-19 is now an established risk factor, surgeons may need to adopt more aggressive prophylactic strategies for these patients.
Refined Risk Stratification
Currently, the Caprini score is the gold standard for predicting VTE. The authors suggest that a history of COVID-19 should perhaps be integrated as a formal, weighted variable in these assessments. If a patient is flagged for "COVID-19 history," it may necessitate more robust pharmacological prophylaxis (such as extended-duration anticoagulation therapy) or the implementation of mechanical compression devices for a longer period during the recovery phase.
Informed Consent
Patients must now be fully informed of the potential risks associated with their viral history. Surgeons have a responsibility to include COVID-19 status in their pre-operative counseling, allowing patients to make educated decisions about the timing of their procedures.
The Path Forward
The researchers are careful to emphasize that while this study identifies a clear association, it is not the final word. Further large-scale, prospective studies are required to establish a causal link and to determine exactly how long the "increased risk" window remains open after an infection. Is the risk higher for those who had COVID-19 within the last six months, or does it persist for years? These are the questions that will define the next phase of research.
About the Authors and Institutional Context
This study is a testament to the rigorous academic work being conducted at institutions like the Penn State College of Medicine. By leveraging national hospital datasets, researchers can identify patterns that might be invisible to individual practitioners.
The publication of this research in Plastic and Reconstructive Surgery—the official journal of the American Society of Plastic Surgeons—ensures that these findings will reach the desks of leading surgeons globally. As the medical industry continues to grapple with the long-tail effects of the pandemic, such evidence-based research remains the only path toward improving patient safety and refining the standards of care in body contouring and reconstructive surgery.
For practitioners and patients alike, the message is clear: the history of COVID-19 is no longer just a detail in a medical chart; it is a vital clinical indicator that demands increased vigilance in the surgical suite.
Source: Incidence of Postoperative Venous Thromboembolism following Panniculectomy in Patients with History of COVID-19 (doi: 10.1097/PRS.0000000000012202). Published in Plastic and Reconstructive Surgery, November 2025.
Wolters Kluwer is a global leader in professional information and software solutions, supporting the medical community through the publication of high-impact research like that found in the Lippincott portfolio.
About the Author
